OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Gastroenterology is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
The utility of liver biopsy in 2020	76
Cancer-associated fibroblasts in cholangiocarcinoma	42
Panorama of mediators in postpancreatitis diabetes mellitus	39
Gaining resilience and reducing stress in the age of COVID-19	34
Metabolic dysfunction-associated fatty liver disease: a year in review	33
Peutz-Jeghers syndrome	30
Breastfeeding and the developmental origins of mucosal immunity: how human milk shapes the innate and adaptive mucosal immune systems	30
New targets in inflammatory bowel disease therapy: 2021	30
Radiation enteritis: from diagnosis to management	29
Update on chronic intestinal pseudo-obstruction	29
Recent insights into trace element deficiencies: causes, recognition and correction	26
Gut microbiota and sepsis: from pathogenesis to novel treatments	26
Molecular classification of cholangiocarcinoma	25
Cholangiocarcinoma in patients with primary sclerosing cholangitis	25
The burden of cost in inflammatory bowel disease: a medical economic perspective	23
Opioid-induced esophageal dysfunction	22
The gut microbiome as a predictor of low fermentable oligosaccharides disaccharides monosaccharides and polyols diet efficacy in functional bowel disorders	21
Role of gut–kidney axis in renal diseases and IgA nephropathy	20
Protein-losing enteropathy	19
Refeeding syndrome: update and clinical advice for prevention, diagnosis and treatment	19
Autoimmune pancreatitis type 2	19
Primary biliary cholangitis: pathogenic mechanisms	18
Early detection of pancreatic cancer	18
Advances in the treatment of gastric cancer: 2020–2021	18
Diagnosis and management of Clostridioides difficile infection in patients with inflammatory bowel disease	18

The prevention of gastric cancer by Helicobacter pylori eradication	18
Diabetes in chronic pancreatitis: risk factors and natural history	17
Gastrointestinal symptoms in COVID-19: the long and the short of it	16
Cancer cachexia: a multifactoral disease that needs a multimodal approach	16
Why antibiotics should not be used to treat Shiga toxin-producing Escherichia coli infections	16
Gastroparesis and functional dyspepsia: different diseases or different ends of the spectrum?	15
Immune contexture of cholangiocarcinoma	15
New systemic agents for hepatocellular carcinoma: an update 2020	15
Tracking COVID-19 via sewage	15
Diet and cancer of the esophagus and stomach	15
Integration of telemedicine into clinical practice for inflammatory bowel disease	14
Intravenous fluid resuscitation in the management of acute pancreatitis	14
Primary biliary cholangitis: treatment	13
Faecal microbiota replacement to eradicate antimicrobial resistant bacteria in the intestinal tract – a systematic review	13
Can SARS-CoV-2 be transmitted via faeces?	13
Robotics in flexible endoscopy: current status and future prospects	13
Endoscopic eradication therapy for Barrett's oesophagus: state of the art	13
Severe acute respiratory syndrome coronavirus-2-associated cholangiopathies	12
EsoFLIP for esophageal dilation: proposed advantages	12
Endoscopic diagnosis and management of gastric subepithelial lesions	12
Approaches to diet therapy for eosinophilic esophagitis	12
Bone loss in patients with inflammatory bowel disease: cause, detection and treatment	12
Advances in cirrhotic cardiomyopathy	12
The importance of anal cancer screening and high-resolution anoscopy to gastroenterology practice	11
Dysregulated lipid metabolism in colorectal cancer	11
The rise of antibiotic resistance in Campylobacter	11
Hepatic manifestations of cystic fibrosis	11
The impact of inflammatory bowel disease on women's lives	11
Advancing flexible endoscopy to natural orifice transluminal endoscopic surgery	11
Mesenchymal stem cell therapy for liver disease: current status and future perspectives	11
The role of bariatric surgery in the management of nonalcoholic steatohepatitis	11
Social media in inflammatory bowel disease: the patient and physician perspective	10
Distinguishing diabetes secondary to pancreatic diseases from type 2 diabetes mellitus	10
Diet and carcinogenesis of gastric cancer	10
The potential of microbiome replacement therapies for Clostridium difficile infection	9
Immunotherapy in cholangiocarcinoma	9
The future of telemedicine and wearable technology in IBD	9
Cellular senescence in the cholangiopathies	9
Coronavirus disease-2019: implications for the gastroenterologist	9
Advances in the treatment of biliary tract cancers	9
Advances in the treatment of gastric cancer	9
Noninvasive assessment oesophageal varices: impact of the Baveno VI criteria	8
Novel treatment options for acute hepatic porphyrias	8
Diet as a treatment for inflammatory bowel disease: is it ready for prime time?	8
Noninvasive strategies for colorectal cancer screening: opportunities and limitations	8
Single-use duodenoscopes: where are we and where are we going?	8
Host immune interactions in chronic inflammatory gastrointestinal conditions	8
Proton pump inhibitors: misconceptions and proper prescribing practice	8
Current endoscopic approaches to biliary strictures	8
Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic	7

Neoadjuvant therapy in pancreatic cancer: a review and update on recent trials	7
Macrophages in cholangiopathies	7
Type 3 autoimmune pancreatitis (immune checkpoint inhibitor-induced pancreatitis)	7
Celiac disease: clinical update	7
The role of magnetic sphincter augmentation in the treatment of gastroesophageal reflux disease	7
Diabetes and pancreatic cancer: recent insights with implications for early diagnosis, treatment and prevention	7
The treatment approach to inflammatory bowel disease in 2020	7
Signatures in drug-induced liver injury	7
Small bowel radiology	7
Macronutrients, microbiome and precision nutrition	7
Fatigue in inflammatory bowel disease: a problematic ailment	7
How to advise patients on the risk of chronic proton pump inhibitor therapy	7
Dietary interventions and irritable bowel syndrome – what really works?	7
Multidisciplinary management of perianal Crohn's disease	7
Mechanisms of autoimmune hepatitis	7
Statins for treatment of chronic liver disease	6
When is parenteral nutrition indicated in the hospitalized, acutely ill patient?	6
Impact of gastroesophageal reflux disease on idiopathic pulmonary fibrosis and lung transplant recipients	6
Novel treatments for alcoholic hepatitis	6
Endoscopic methods for the detection and treatment of gastric cancer	6
Magnetic sphincter augmentation versus fundoplication for gastroesophageal reflux disease: pros and cons	6
Coagulation testing and management in liver disease patients	6
Acute-on-chronic liver failure: update on pathogenesis, therapeutic targets, predictive models, and liver transplantation	6
Role of albumin in the treatment of decompensated liver cirrhosis	6
Molecular targets and the use of biologics in the management of small bowel fibrosis in inflammatory bowel disease	6
Impact of bariatric surgery on gastroesophageal reflux disease and esophageal motility	6
Genetically engineered animal models of biliary tract cancers	6
Autoimmune hepatitis: from immunopathogenesis to diagnostic and therapeutic innovation	6
Should high-fiber diets be recommended for patients with inflammatory bowel disease?	6
Refractory coeliac disease: what should we be doing different?	6
Duodenal chemosensory system: enterocytes, enteroendocrine cells, and tuft cells	6
Management of refractory inflammatory bowel disease	6
Complications of chronic pancreatitis in children	6
Third space endoscopy: the future of treating gastrointestinal dysmotility	6
Early detection of pancreatic cancer: current state and future opportunities	6
Management of regurgitation in patients with gastroesophageal reflux disease	6